US Patent Issued to 89bio on July 8 for "Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates" (American, Israeli Inventors)

ALEXANDRIA, Va., July 9 -- United States Patent no. 12,350,314, issued on July 8, was assigned to 89bio Inc. (San Francisco).

"Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates" was invented by Boris Schwartsburd (Rehovot, Israel) and Shaji Joseph (Sunnyvale, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate."

The patent was filed on Nov. 8, 2023, under Application No. 18/504,561.

*For...